Anthem Biosciences IPO - D&M Vertical Continues to Drive CRDMO Business
Anthem Biosciences is looking to raise about US$397m in its India IPO. In this note, we will talk about the RHP updates.
687 Views
Pharmaceuticals: Indian CRDMOs at a pivotal point, scale-up key
The Indian Contract Research, Development, and Manufacturing Organizations (CRDMO) market is poised to grow rapidly at a CAGR of ~13.4% over 2024...
148 Views
Thematic Report: Can Tariffs Undermine India’s Pharma Advantage?
India leads in generic medicine exports, offering significant cost savings in R&D and manufacturing compared to the US. The country's CRDMO sector...
731 Views
NIFTY MIDCAP150 Index Rebalance Preview: 15 Potential Changes in March
There could be 15 changes in March. Estimated one-way turnover is 9.8% and round-trip trade is INR 26.5bn. With over US$43bn tracking the index...
347 Views
2025: A Review of Our Hits and Misses in the Indian Primary Market
In 2025, Indian mainboard IPOs raised INR 1.83 trillion; this insight reviews our hits and misses in Indian Primary Market for companies with post...
187 Views